151 related articles for article (PubMed ID: 31812464)
1. A Phase 2/3 double blinded, randomized, placebo-controlled study in healthy adult participants in Vietnam to examine the safety and immunogenicity of an inactivated whole virion, alum adjuvanted, A(H5N1) influenza vaccine (IVACFLU-A/H5N1).
Duong TN; Thiem VD; Anh DD; Cuong NP; Thang TC; Huong VM; Chien VC; Phuong NTL; Montomoli E; Holt R; Scorza FB; Flores J; Tewari T
Vaccine; 2020 Feb; 38(6):1541-1550. PubMed ID: 31812464
[TBL] [Abstract][Full Text] [Related]
2. A phase 2/3 double-blind, randomized, placebo-controlled study to evaluate the safety and immunogenicity of a seasonal trivalent inactivated split-virion influenza vaccine (IVACFLU-S) in healthy adults in Vietnam.
Lan PT; Toan NT; Thang HA; Thang TC; Be LV; Thai DH; Huong VM; Nga NT; Tang Y; Holt R; Francesco BS; Flores J; Tewari T
Hum Vaccin Immunother; 2019; 15(12):2933-2939. PubMed ID: 31070986
[No Abstract] [Full Text] [Related]
3. Randomized, double-blind, multi-center, phase III clinical trial to evaluate the immunogenicity and safety of MG1109 (egg-based pre-pandemic influenza A/H5N1 vaccine) in healthy adults.
Song JY; Choi MJ; Noh JY; Choi WS; Cheong HJ; Wie SH; Lee JS; Woo GJ; Lee SH; Kim WJ
Hum Vaccin Immunother; 2017 May; 13(5):1190-1197. PubMed ID: 27996363
[TBL] [Abstract][Full Text] [Related]
4. The safety and immunogenicity of a cell-derived adjuvanted H5N1 vaccine - A phase I randomized clinical trial.
Cheng A; Hsieh SM; Pan SC; Li YH; Hsieh EF; Lee HC; Lin TW; Lai KL; Chen C; Shi-Chung Chang S; Chang SC
J Microbiol Immunol Infect; 2019 Oct; 52(5):685-692. PubMed ID: 31255574
[TBL] [Abstract][Full Text] [Related]
5. Clinical testing of an inactivated influenza A/H5N1 vaccine candidate in a double-blinded, placebo-controlled, randomized trial in healthy adults in Vietnam.
Phan TL; Ho VT; Vu MH; Nguyen TN; Duong HT; Holt R; Wahid R; Donnelly J; Flores J
Vaccine; 2016 Oct; 34(45):5449-5456. PubMed ID: 27591953
[TBL] [Abstract][Full Text] [Related]
6. Randomized safety and immunogenicity trial of a seasonal trivalent inactivated split virion influenza vaccine (IVACFLU-S) in healthy young Vietnamese adults.
Anh DD; Thiem VD; Anh NTH; Huong VM; Nga NT; Thang TC; Thai DH; Chien VC; Holt R; Wahid R; Flores J; Berlanda Scorza F; Taylor DN
Vaccine; 2016 Oct; 34(45):5457-5462. PubMed ID: 27567493
[TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of an MF59(®)-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly.
Vesikari T; Forstén A; Herbinger KH; Cioppa GD; Beygo J; Borkowski A; Groth N; Bennati M; von Sonnenburg F
Vaccine; 2012 Feb; 30(7):1388-96. PubMed ID: 22192847
[TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity of adjuvanted inactivated split-virion and whole-virion influenza A (H5N1) vaccines in children: a phase I-II randomized trial.
Wu J; Liu SZ; Dong SS; Dong XP; Zhang WL; Lu M; Li CG; Zhou JC; Fang HH; Liu Y; Liu LY; Qiu YZ; Gao Q; Zhang XM; Chen JT; Zhong X; Yin WD; Feng ZJ
Vaccine; 2010 Aug; 28(38):6221-7. PubMed ID: 20638454
[TBL] [Abstract][Full Text] [Related]
9. Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults.
Nolan TM; Richmond PC; Skeljo MV; Pearce G; Hartel G; Formica NT; Höschler K; Bennet J; Ryan D; Papanaoum K; Basser RL; Zambon MC
Vaccine; 2008 Aug; 26(33):4160-7. PubMed ID: 18599164
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial.
Wu J; Fang HH; Chen JT; Zhou JC; Feng ZJ; Li CG; Qiu YZ; Liu Y; Lu M; Liu LY; Dong SS; Gao Q; Zhang XM; Wang N; Yin WD; Dong XP
Clin Infect Dis; 2009 Apr; 48(8):1087-95. PubMed ID: 19281330
[TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial.
Lin J; Zhang J; Dong X; Fang H; Chen J; Su N; Gao Q; Zhang Z; Liu Y; Wang Z; Yang M; Sun R; Li C; Lin S; Ji M; Liu Y; Wang X; Wood J; Feng Z; Wang Y; Yin W
Lancet; 2006 Sep; 368(9540):991-7. PubMed ID: 16980114
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of influenza A(H5N1) vaccine stored up to twelve years in the National Pre-Pandemic Influenza Vaccine Stockpile (NPIVS).
Oshansky CM; Zhou J; Gao Y; Schweinle JE; Biscardi K; DeBeauchamp J; Pavetto C; Wollish A; ; Webby RJ; Cioce V; Donis RO; Bright RA
Vaccine; 2019 Jan; 37(3):435-443. PubMed ID: 30553570
[TBL] [Abstract][Full Text] [Related]
13. A phase II, open-label, multicentre study to evaluate the immunogenicity and safety of an adjuvanted prepandemic (H5N1) influenza vaccine in healthy Japanese adults.
Nagai H; Ikematsu H; Tenjinbaru K; Maeda A; Dramé M; Roman FP
BMC Infect Dis; 2010 Nov; 10():338. PubMed ID: 21108818
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of a live attenuated influenza H5 candidate vaccine strain A/17/turkey/Turkey/05/133 H5N2 and its priming effects for potential pre-pandemic use: a randomised, double-blind, placebo-controlled trial.
Pitisuttithum P; Boonnak K; Chamnanchanunt S; Puthavathana P; Luvira V; Lerdsamran H; Kaewkungwal J; Lawpoolsri S; Thanachartwet V; Silachamroon U; Masamae W; Schuetz A; Wirachwong P; Thirapakpoomanunt S; Rudenko L; Sparrow E; Friede M; Kieny MP
Lancet Infect Dis; 2017 Aug; 17(8):833-842. PubMed ID: 28533093
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity of avian influenza A/Anhui/01/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trial.
Belshe RB; Frey SE; Graham IL; Anderson EL; Jackson LA; Spearman P; Edupuganti S; Mulligan MJ; Rouphael N; Winokur P; Dolor RJ; Woods CW; Walter EB; Chen WH; Turley C; Edwards KM; Creech CB; Hill H; Bellamy AR;
JAMA; 2014 Oct; 312(14):1420-8. PubMed ID: 25291578
[TBL] [Abstract][Full Text] [Related]
16. MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults.
Banzhoff A; Gasparini R; Laghi-Pasini F; Staniscia T; Durando P; Montomoli E; Capecchi PL; di Giovanni P; Sticchi L; Gentile C; Hilbert A; Brauer V; Tilman S; Podda A
PLoS One; 2009; 4(2):e4384. PubMed ID: 19197383
[TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of two different doses of a Vero cell-derived, whole virus clade 2 H5N1 (A/Indonesia/05/2005) influenza vaccine.
Tambyah PA; Wilder-Smith A; Pavlova BG; Barrett PN; Oh HM; Hui DS; Yuen KY; Fritsch S; Aichinger G; Loew-Baselli A; van der Velden M; Maritsch F; Kistner O; Ehrlich HJ
Vaccine; 2012 Jan; 30(2):329-35. PubMed ID: 22080174
[TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity of an influenza vaccine A/H5N1 (A/Vietnam/1194/2004) when coadministered with a heat-labile enterotoxin (LT) adjuvant patch.
Glenn GM; Thomas DN; Poffenberger KL; Flyer DC; Ellingsworth LR; Andersen BH; Frech SA
Vaccine; 2009 Dec; 27 Suppl 6():G60-6. PubMed ID: 20006142
[TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children.
Nolan T; Richmond PC; Formica NT; Höschler K; Skeljo MV; Stoney T; McVernon J; Hartel G; Sawlwin DC; Bennet J; Ryan D; Basser RL; Zambon MC
Vaccine; 2008 Nov; 26(50):6383-91. PubMed ID: 18801398
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and safety of MF59-adjuvanted H5N1 influenza vaccine from infancy to adolescence.
Vesikari T; Karvonen A; Tilman S; Borkowski A; Montomoli E; Banzhoff A; Clemens R
Pediatrics; 2010 Oct; 126(4):e762-70. PubMed ID: 20819892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
